Get the Stockscreener App
24.72
4.35%
1.03
After Hours:
24.72
Spyglass Pharma Inc stock is traded at $24.72, with a volume of 47,120.
It is up +4.35% in the last 24 hours and down -14.64% over the past month.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
See More
Previous Close:
$23.69
Open:
$23.67
24h Volume:
47,120
Relative Volume:
0.61
Market Cap:
$826.83M
Revenue:
Net Income/Loss:
$-43.60M
P/E Ratio:
-4.6735
EPS:
-5.2894
Net Cash Flow:
1W Performance:
+0.41%
1M Performance:
-14.64%
6M Performance:
-0.04%
1Y Performance:
+0.00%
1-Day Range:
$23.50
$24.93
1-Week Range:
$22.80
$25.79
52-Week Range:
$17.06
$32.44
Spyglass Pharma Inc Stock (SGP) Company Profile
Name
Spyglass Pharma Inc
Sector
Industry
Phone
949-284-6904
Address
27081 ALISO CREEK ROAD, ALISO VIEJO
Compare SGP vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGP
Spyglass Pharma Inc
|
24.72 | 826.83M | 0 | -43.60M | 0 | -5.2894 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Spyglass Pharma Inc Stock (SGP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-26 | Initiated | Raymond James | Outperform |
| Mar-10-26 | Initiated | H.C. Wainwright | Buy |
| Mar-03-26 | Initiated | Citigroup | Buy |
| Mar-03-26 | Initiated | Jefferies | Buy |
| Mar-03-26 | Initiated | Leerink Partners | Outperform |
| Mar-03-26 | Initiated | Stifel | Buy |
View All
Spyglass Pharma Inc Stock (SGP) Latest News
H.C. Wainwright reiterates SpyGlass Pharma stock rating at buy By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates SpyGlass Pharma stock rating at buy - Investing.com
H.C. Wainwright reiterates SpyGlass Pharma stock rating at buy By Investing.com - Investing.com Canada
SpyGlass Pharma Acquires Advanced Vision Science, Securing Commercial IOL Supply, Accelerating Lens Portfolio Expansion - VisionMonday.com
SpyGlass Pharma Acquires Advanced Vision Science for $13 Million - Minichart
SpyGlass Pharma Acquires Advanced Vision Science, Inc. - GlobeNewswire
Spyglass Pharma (NASDAQ:SGP) Shares Down 4.5%What's Next? - MarketBeat
Spyglass Pharma, Inc. (NASDAQ:SGP) Stock Has Average Target Price of $44.00 - MarketBeat
SpyGlass Pharma (NasdaqGS:SGP) Stock Price - Simply Wall Street
Spyglass Pharma (NASDAQ:SGP) Upgraded at Wall Street Zen - MarketBeat
Spyglass Pharma (NASDAQ:SGP) Trading Down 5.3%Should You Sell? - MarketBeat
SpyGlass Pharma at Citigroup summit: glaucoma lens nears phase iii By Investing.com - Investing.com Australia
SpyGlass Pharma at Citigroup summit: glaucoma lens nears phase iii By Investing.com - Investing.com Canada
SpyGlass Pharma (SGP) Holds Near $27.55 as Traders Eye the $28.93 CeilingBreadth Thrust - dars.gov.et
SpyGlass Pharma (SGP) Holds Near $27.55 as Traders Eye the $28.93 CeilingMoney Flow Index - careplusvn.com
SpyGlass Pharma Expands to Bigger HQ in Irvine - Orange County Business Journal
SpyGlass Pharma to Participate in Upcoming Investor Conferences - GlobeNewswire
Three September conferences will include SpyGlass Pharma. Two talks will be webcast. - Stock Titan
SpyGlass Pharma Celebrates Grand Opening of New Irvine Headquarters, Positioning Itself for First Product Launch and Custom R&D Space - Moomoo
SpyGlass Pharma Celebrates Grand Opening of New Irvine Headquarters, Positioning Itself for First Product Launch and Custom R&D Space - PR Newswire
SpyGlass (SGP) Trading: Closes 1.00% Lower at $26.25; Traders Can Monitor the $24.94-$27.56 Range for the Current SessionContinuation Pattern Picks - vinanet.vn
SpyGlass (SGP) Earnings Reading: EPS Misses Its Estimate in the Available Record; Share Move - vinanet.vn
SpyGlass (SGP): Finishes 1.91% Lower at $26.71; Technical Setup: the Current Price Sits Inside the Supplied Technical Range in the Available RecordWyckoff Accumulation - vinanet.vn
SpyGlass (SGP): Finishes 1.91% Lower at $26.71; Technical Setup: the Current Price Sits Inside the Supplied Technical Range in the Available RecordLate Stage Breakouts - siam.in
SpyGlass (SGP) Financial Update: Profit Per Share Falls Below Its Benchmark under the Current Snapshot - vinanet.vn
SpyGlass Pharma (SGP) Slides 2.4% as Shares Test Mid-Range Support ZoneBlock Trade Flow - vinanet.vn
SpyGlass Pharma (SGP) Slides 2.4% as Shares Test Mid-Range Support ZoneMutual Fund Flow - siam.in
Spyglass Pharma (NASDAQ:SGP) Upgraded to "Moderate Buy" at Raymond James Financial - MarketBeat
Analysts Offer Insights on NA Companies: Ottobock SE & Co. KGaA (OtherOBCKF), SpyGlass Pharma (Nasdaq: SGP) and Figure Technology Solutions, Inc. Class A (FIGR) - The Globe and Mail
Analysts Offer Insights on NA Companies: Ottobock SE & Co. KGaA (OtherOBCKF), SpyGlass Pharma (Nasdaq: SGP) and Figure Technology Solutions, Inc. Class A (FIGR) - theglobeandmail.com
SpyGlass Pharma, Inc. (NASDAQ: SGP) Share Price, SGP Stock News, SGP Share Price & Updates - Kalkine
SpyGlass Pharma, Inc. (NASDAQ: SGP) Share Price, SGP Stock News, SGP Share Price & Updates - kalkine.ca
Raymond James Initiates SpyGlass Pharma(SGP.US) With Buy Rating, Announces Target Price $39 - Moomoo
Raymond James initiates SpyGlass Pharma stock coverage with outperform rating - Investing.com
Raymond James initiates SpyGlass Pharma stock coverage with outperform rating - Investing.com India
Raymond James initiates SpyGlass Pharma stock coverage with outperform rating - Investing.com Canada
Q3 EPS Estimates for Spyglass Pharma Decreased by Analyst - MarketBeat
SpyGlass Pharma Reports Q2 Financials, Provides Corporate Updates - visionmonday.com
SpyGlass Pharma Ord shs (Proposed) (SGP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Spyglass Pharma, Inc. (NASDAQ:SGP) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
SpyGlass Pharma 2Q 2026: Net loss $(19.9)M, EPS $(0.59) — 10-Q Summary - TradingView
[10-Q] SpyGlass Pharma, Inc. Quarterly Earnings Report - Stock Titan
SpyGlass Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
SpyGlass Pharma reports $19.9M Q2 net loss, $234.2M cash and investments as of June 30, 2026 - TradingView
SpyGlass Pharma Q2 net loss widens on higher expenses - TradingView
SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - Yahoo Finance
SpyGlass Pharma Insiders Enjoying US$1.1m Appreciation On US$2.16m Investment - webull.com
SpyGlass Pharma (SGP) Rallies 3.08% to $24.41 as Ophthalmic Focus Draws Fresh BuyingLow Vol Factor - dars.gov.et
SpyGlass Pharma (SGP) Climbs 5.5% as Bulls Eye Resistance at $26.24Catalyst Driven Stocks - dars.gov.et
SpyGlass Pharma (SGP) Rallies 3.08% to $24.41 as Ophthalmic Focus Draws Fresh BuyingMedian Line - dars.gov.et
Spyglass Pharma Inc Stock (SGP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Spyglass Pharma Inc Stock (SGP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Behbahani Ali | Director |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Florence Anthony A. Jr. | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| BASKETT FOREST | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| New Enterprise Associates 17, | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Yang Rick | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Makhzoumi Mohamad | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| SANDELL SCOTT D | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Chang Carmen | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Walker Paul Edward | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Mathers Edward T | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
3.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):